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lack of an RCT makes formal technology assessment vs. alternative treatment (e.g., 
best supportive care [BSC]) challenging. In such instances, naïve indirect comparison 
based on historical controls is typically employed. We present a method for estimating 
outcomes for untreated patients when appropriate historical controls are not available, 
by using data from non-responders in an uncontrolled trial. METHODS: Ofatumumab 
was licensed for ﬂ udarabine- and alemtuzumab-refractory chronic lymphocytic leukaemia 
(FA-Ref CLL) based on results of an uncontrolled trial (Hx-CD20-406). To evaluate the 
cost-effectiveness of ofatumumab vs. BSC from the UK National Health Service perspec-
tive, a partitioned survival analysis model was developed. Progression free survival (PFS) 
and overall survival (OS) for ofatumumab were estimated by ﬁ tting Weibull survival 
functions to failure time data for all FA-Ref patients in Hx-CD20-406. Following a litera-
ture search, no suitable historical control representing BSC could be identiﬁ ed; therefore 
hazard ratios for PFS and OS for BSC vs. ofatumumab were estimated by ﬁ tting Cox 
regression models to data for non-responders vs. all FA-Ref patients. Costs and utilities 
were taken from both published and unpublished sources. RESULTS: BSC patients 
(approximated by non-responders) were estimated to achieve 4.7 months PFS, 11.3 
months OS, 0.50 QALYs, and expected lifetime costs of £4,876. Ofatumumab patients 
were estimated to reach 6.5 months PFS, 17.9 months OS, 0.77 QALYs, with expected 
lifetime costs of £43,828. CONCLUSIONS: The novel approach presented permits a 
practical alternative for estimating cost-effectiveness when neither an RCT nor appro-
priate historical control can be identiﬁ ed. Further research should be conducted using 
established data sets to validate the methodology, and to address potential limitations, 
e.g. unobserved differences between treatment groups, and potential beneﬁ ts of treat-
ment in patients classiﬁ ed as non-responders.
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OBJECTIVES: While randomized control trials (RCT) are the gold standard for drug 
approval, there is often a lack of data directly comparing different treatment options. 
An indirect comparison of the treatment effects may serve as a proxy for a head-to-
head RCT, however, naively comparing treatments using published trial data without 
adjusting for distribution differences in patient characteristics and prognostic factors 
can result in misleading conclusions. a novel matched-adjusted approach to indirectly 
compare absolute survival estimates (median overall survival (OS) or progression free 
survival (PFS)) for competitive treatment options is presented. METHODS: This 
proposed approach requires patient-level data for one of the treatments and summary 
data of patient characteristics and survival outcomes for the comparator of interest. 
Using this proposed method, the researcher would ﬁ rst decide on one or two matching 
variables that are prognostic for survival, and apply a program involving an extension 
of a common SAS 9.2 procedure, Proc Surveyselect, to select 1000 random repeated 
sub-samples from the original population with the same distribution of matched 
variables. The analysis also requires programming statements using ODS and survival 
analysis procedures. The median OS or PFS estimates are computed for each boot-
strapped sample and a 95% conﬁ dence interval (CI) is inferred around the mean of 
the sampled survival estimates. These absolute survival estimates, based on the 
adjusted population, can then be compared to the absolute survival estimates reported 
in published literature of the comparator treatment. CONCLUSIONS: In the absence 
of head-to-head RCT data, an adjusted indirect comparison accounts for observed 
differences between populations making them more comparable and results in an effect 
of treatment exposure on survival outcomes that is less likely due to confounders. 
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OBJECTIVES: The objectives of this study are: 1) to systematically review the methods 
used in developing cost estimates in the recent German health economic literature; 
and 2) to examine the methodological approaches in terms of analytical framework, 
cost components, resource use and cost data sources in light of the national Institute 
for Quality and Efﬁ ciency in Healthcare guidelines. METHODS: The MEDLINE 
database was searched for studies published between 1-Jan-2006 and 31-Dec-2008 
estimating direct and/or indirect costs of health care interventions in Germany. 
Detailed information on the perspective of the analysis, time horizon, resource use 
categories, costing approach, valuation of resource use, resource use and unit cost/
price data sources were systematically collected. RESULTS: The literature search 
returned citations to 122 articles, of which 47 met the inclusion/exclusion criteria. 
Nearly half of the selected articles (23) adopted the societal perspective and 21 
(44.7%) the perspective of German Statutory Health Insurance funds. In nearly three 
quarters of the studies (35) the time-horizon of the base-case analysis was no longer 
than one year. Direct medical costs were reported in almost all articles; 25 studies 
(53.2%) assessed only this cost category. Among the most common unit cost sources 
of health care services were reimbursement fees for outpatient and hospital services, 
together with market prices for drugs and medical devices, mentioned in 43 (91.5%) 
and 39 (83.0%) articles, respectively. CONCLUSIONS: Although the variability in 
the studies reviewed was very high, some common features emerged. Firstly, most cost 
estimates focus on direct medical costs only. Secondly, a comprehensive list or at least 
an exhaustive discussion of the relevant resource use is usually missing. Finally, the 
time-horizon is often too short to capture all relevant cost drivers and the assessment 
of the medical resource use not always consistent with the perspective of the 
analysis.
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OBJECTIVES: Economic analyses that take a societal perspective need to incorporate 
estimates of lost productivity due to premature death. Such estimates are likely to vary 
substantially across countries, making it a challenge to assess the value of alternative 
medical interventions on a global basis. Our goal was to develop a generic, web-based 
software tool based on rigorous analytic methods that would enable researchers to 
assess the expected discounted present value of lost productivity for persons who die 
prematurely at various ages in selected developed and emerging nations. METHODS: 
An analytic model framework was developed to estimate the expected discounted 
present value of lost productivity due to premature mortality from a societal perspec-
tive using a human capital approach (with value attached to household work, as data 
permitted). Key model inputs included life tables, labor force participation rates, 
wages, and discount rates. Default input parameter values were based on each coun-
try’s national statistics, as available, or via generic “global” estimates when such data 
were lacking. RESULTS: Model results were generated for 20 countries around the 
world, and varied substantially based on patient age at death and the economic region 
in which a country is located. For illustration purposes, the discounted present values 
of lost productivity for a person who dies at age 25–29 in the US, Brazil, and Sweden 
were estimated to be $US 945,162, 124,795, and 805,740, while the corresponding 
values for those who die at age 45–49 were 622,248, 76,976, and 480,480. The web-
based interface allows researchers to select the country of interest, modify default 
values, and conduct sensitivity analyses. CONCLUSIONS: This generic web-based 
software tool allows researchers to easily incorporate the value of lost productivity 
due to premature mortality into economic analyses that take a societal perspective, 
and provides estimates for many different developed and emerging countries.
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OBJECTIVES: The inclusion of loss productivity costs in pharmacoeconomic studies 
is still a subject of considerable debate. The aim of this study was to quantify the work 
impairment due to general health status in Poland with the Productivity and Activity 
Impairment: General Health (WPAI-GH) Questionnaire. METHODS: Data were 
obtained from a survey that incorporated the WPAI-GH questionnaire and informa-
tion on burden of care for a sick family member during computer-assisted personal 
interview in a representative sample of the Polish general population aged more than 
15 years. There were 2019 respondents in total, gathered in two waves in January 
and May 2010. RESULTS: The total population comprised 795 subjects in paid jobs. 
Subjects reported 4.5% work time missed (absenteeism) during the past 7 days. 
Impairment while at work (presenteeism) amounted to 13.9% of total time. The 
overall work productivity loss (absenteeism plus presenteeism) equalled 15.2%. 
Impairment in performing daily activity was 15.6% in the past 7 days. Observed 
percentages were in general higher in subject from the ﬁ rst wave of study (January 
2010) than from second wave (May 2010)—differences did not reach statistical sig-
niﬁ cance. The general tendency of a higher absenteeism and a lower presenteeism 
values among men than among women were observed. CONCLUSIONS: Productivity 
and Activity Impairment measured by WPAI-GH in the Polish population are similar 
to these observed in other European countries and the U.S. Moderate differences 
between values estimated in January and May suggest limited impact of seasonal 
diseases such as inﬂ uenza on productivity.
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OBJECTIVES: There exists no standardised list of unit costs (UC) for use in economic 
evaluations in Spain. Tariffs published by the 17 Autonomous Communities (ACs) 
are often used as a proxy for costs. We explored the structure and contents of AC 
tariff lists and tariff ranges for common resource use items. METHODS: Current tariff 
lists published in the Ofﬁ cial Bulletins from 16 Spanish ACs were retrieved. Tariffs 
for key health services in the following categories were extracted: specialist and A&E 
visits, hospitalization, investigations, procedures, laboratory tests, and episodes of care 
(DRGs). We qualitatively assessed structure and contents of tariff lists, item content 
for selected items. Ranges, normal mean and weighted mean (according to 
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demographic size of ACs) were calculated for selected tariffs. RESULTS: We observed 
lack of consistency in structure and contents of tariff lists and in tariff levels, as 
exempliﬁ ed by: different categorization of services; incomplete listing of services; dif-
ferent terminologies; different levels of detail for common services (e.g. MRI: 2–127 
options by body area and/or complexity); wide ranges of tariffs for most items (e.g. 
specialist visit: c56–c191, general ward per diem: c82–c569, simple MRI: c120–c634). 
Wide variations were also observed for other diagnostic investigations, (non-)surgical 
procedures, laboratory tests and DRGs. CONCLUSIONS: Wide ranges in tariffs for 
health resources commonly used in economic evaluations were identiﬁ ed across ACs, 
with a difference between minimum and maximum values of at least factor 2. There 
exists no evidence on how tariffs are calculated and if they reﬂ ect real cost. Available 
AC tariffs should be used with caution and a simple or weighted average across AC 
tariff lists may be used as proxies for nation-wide costs. Elaboration of a nation-wide 
list would avoid possible bias from analysts in the selection of cost values to obtain 
given results.
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OBJECTIVES: We examined the association between economic evaluation studies 
performed in Spain in 1983–2008 and the burden of disease in the population. 
METHODS: Cross-sectional observational study. Electronic databases (Pubmed/
MEDLINE, SCOPUS, ISI Web of Knowledge, CRD, IME, IBECS) and reports from 
public agencies were systematically reviewed. Inclusion and exclusion criteria and a 
set of variables were deﬁ ned to analyze the characteristics of the papers selected. Using 
the Global Burden of Disease (GBD) study classiﬁ cation the following measures were 
calculated: years of life lost (YLLs), years lived with disability (YLDs), disability-
adjusted life-years (DALYs), and mortality by cause. Correlation and linear regression 
models were used. RESULTS: Cardiovascular diseases (15.7%), infectious and para-
sitic diseases (15.3%), and malignant neoplasms (13.2%) were the conditions most 
commonly addressed. Accidents and injuries, congenital anomalies, oral conditions, 
nutritional deﬁ ciencies and other neoplasms were the categories with a lowest number 
of studies (0.6% from the total for each of them). The disease sub-categories most 
prevalent in the studies were lower respiratory infections (5.7%), ischemic heart 
disease (5.7%), hepatitis B and C (3.3%) and HIV/AIDS (3.1%). For GBD categories 
(n = 20), a correlation was seen with: mortality 0.67 (p = 0.001), DALYs 0.63 (p = 
0.003), YLLs 0.54 (p = 0.014), and YLDs 0.51 (p = 0.018). By diseases sub-categories 
(n = 51), the correlations were low and non statistically signiﬁ cant. CONCLUSIONS: 
There is a mild-moderate association of economic evaluations with the main causes 
of burden of disease. For some conditions, the data show over or under-representation 
of studies related to their burden generated. The burden of disease is a criterion that, 
in combination with efﬁ ciency and equity, would allow to set recommendations to 
guide debates on health research priority setting.
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BACKGROUND: The major focus of the history of economic thought has been 
devoted to deﬁ ning a scientiﬁ c theory of value. An even harder task entails formulating 
a theory of intertemporal value. Work on this theory date back to the birth of modern 
economic thought. For example, some authors have argued that an intertemporal 
utility based theory of value involves the explanation of a quantity which can be 
directly observed and measured in terms of a quantity which cannot. Major current 
debates on discounting therefore surround the need for a scientiﬁ c deﬁ nition and the 
ethics towards intergenerational justice. OBJECTIVES: We investigate how several 
current issues in discounting might be irrelevant by adopting a Neo-Ricardian view 
of intertemporal value by recursively applying valuation of a commodity from value 
of input commodities, thereby simplifying to the Physiocratic School. We further 
investigate how our empirical model might be extended to current utilitarian philoso-
phy. METHODS: We adopt a Srafﬁ an approach and devise a pure value-growth 
matrix that relies only on empirical data. We ﬁ rst derive a 2 × 2 matrix and then a 3 
× 3 matrix. We use health effects, income and a third externality for the derivations. 
RESULTS: It seems that the Neo-Riccardian approach provides the necessary require-
ments towards satisfying a scientiﬁ c deﬁ nition of intertemporal value and allows 
extension of the classical framework of health and wealth with a 3rd dimension of 
externalities. Furthermore, by redeﬁ ning the pure growth term in our 2 × 2 matrix 
with the Ramsey discount rate, our results simplify to current economic theory. 
CONCLUSIONS: Although modern economic theory explains value from a utilitarian 
viewpoint, it seems that it lacks robustness in explaining intertemporal value. There-
fore, we suggest that the Srafﬁ an School of economic thought should also be consid-
ered when attempting to formulate a discount rate for health effects, within a concept 
of sustainable growth.
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OBJECTIVE: To verify the reliability of the methodology used in the manufacturers’ 
Budget Impact Analyses (BIAs) submitted in reimbursement dossier to Polish HTA 
Agency, we compared public payer (National Health Fund—NHF) actual expendi-
tures on selected drugs with their estimated costs. METHODS: BIAs of medicines 
reimbursed for at least one year and assessed previously in Agency were selected for 
the analysis. The BI estimated by the manufacturer in the ﬁ rst year after product’s 
introduction to reimbursement was used. Estimated size of target population was 
compared with the actual one. The actual data was obtained from the NHF. BIAs for 
selected medicines were critically appraised to determine any variables that may have 
affected its reliability. RESULTS: 20 BIAs met inclusion criteria and were included 
into the study. Forty-ﬁ ve percent (9/20) of the BI expenditures were underestimated. 
Median and mean difference between actual and estimated expenditure were 17,22% 
and 30,25% respectively. The overestimation was found in 55% BIAs (11/20); median 
= 262,26%, mean difference = 2267,25%. Population size was underestimated in 65% 
(13/20) of the BIAs. Median and mean difference between actual and estimated popu-
lation were 25,61% and 33,93% respectively. Overestimation of the population was 
found in 35% (7/20) of the BIAs; median = 566,67%, mean difference = 573,28%. 
The main factors that could inﬂ uence differences between predictions and actual 
spending were: underestimated (65%) or overestimated (35%) number of patients 
eligible for treatment, overestimated (30%) or underestimated (25%) market share, 
wrong assumption on 100% compliance (15%). CONCLUSION: The study has dem-
onstrated large variances between predicted budget impact and actual expenditures on 
drugs. It also revealed signiﬁ cant weaknesses in the quality of submitted BIAs, e.g.: errors 
in calculations, very limited data provided by manufacturer that unable to complete revi-
sion and reproduce of ﬁ gures in the calculation.
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As they are currently used thresholds for cost per QALY may provide a disincentive 
for companies to invest in research for therapies that prolong life in conditions with 
an already high treatment cost. Cost per QALY thresholds, although not the sole basis 
for decision making are a major inﬂ uence on whether a technology is considered 
cost-effective by NICE. Discussions have centred on the most appropriate threshold 
level and how its value should be determined. However a consequence of cost per 
QALY thresholds that is not discussed is the impact they may have on future health 
care research. The cost per QALY for renal dialysis has been estimated at £30,0001, 
the higher end of what NICE considers acceptable. We have therefore reached the 
ceiling for the cost of treating renal disease. Assuming that utility is not improved a 
treatment that extends life will be at additional cost and have a cost per QALY greater 
than £30,000. Manufacturers of health care technologies may consider that the risk 
of not getting a product approved on cost-effectiveness grounds is not worth the 
ﬁ nancial investment in its development. As health care costs continue to grow the 
management costs of more conditions will exceed £20,000 per year and future 
research may be stiﬂ ed as manufacturers seek to develop products that replace rather 
than add to current treatments. Since the background treatment cost would cancel out 
in an incremental analysis a treatment could be more cost-effective than the one it 
replaces but perversely can still be at an increased cost which raises the cost per QALY 
of standard treatment above £20,000 or £30,000. As treatment costs for more condi-
tions increase to threshold values (even if they are raised) manufactures may be advised 
to consider realigning their portfolio and investment to other diseases.
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OBJECTIVES: The objective of the CRRéa study is to assess the real daily cost of a 
patient’s stay in ICU in France. We present here preliminary results regarding the 
average time spent per patient by different health caregivers. METHODS: A prospec-
tive multicentric health economic study was performed in 23 ICUs of different French 
hospitals randomly selected from the PMSI database (French National Hospital data-
base). In a one day study, 5 adult patients were randomly selected among patients 
with a simpliﬁ ed severity score ≥ 15 in each ICU. Data on all the resources used, 
treatments administered, biological tests performed, etc. and time spent by different 
health caregiver to take care of each patient over a 24 hour period (direct and indirect 
interventions) were collected through a time and motion analysis method involving 
the professionals themselves. RESULTS: A total of 109 patients (median age = 66 
years, 65% males) of 22 intensive care units (15 polyvalent, 3 surgical and 4 medical 
ICUs) were included. 104 of them were followed over 24 hours (there were 2 deaths 
and 3 early withdrawals). On the day of the study, 84% of patients were mechanically 
